top of page


South Korea approves Jascayd nerandomilast for idiopathic pulmonary fibrosis
South Korea has authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, providing a new national treatment option for patients with progressive lung scarring.

nuaxia
Oct 162 min read


Saudi regulator approves Jascayd for idiopathic pulmonary fibrosis
Saudi Arabia has approved Jascayd for adults with idiopathic pulmonary fibrosis following Phase III evidence showing reduced decline in lung function.

nuaxia
Oct 52 min read


PureTech-Backed Celea Raises $180m to Challenge Established IPF Treatments
New funding will support a pivotal Phase III trial comparing deupirfenidone head-to-head with Roche’s Esbriet as competition intensifies in idiopathic pulmonary fibrosis.

nuaxia
Jul 73 min read


Celea Therapeutics Secures $180m to Advance Phase III IPF Programme
Funding will support the global SURPASS-IPF trial comparing deupirfenidone directly against standard-of-care pirfenidone in idiopathic pulmonary fibrosis.

nuaxia
Jul 52 min read
bottom of page